The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Signal regulatory protein α (SIRPα) is expressed in dendritic cells (DCs) and macrophages.
• SIRPα interacts with CD47, a protein overexpressed on tumor cells.
• This interaction inhibits DC maturation and phagocytosis, suppressing anti-tumor immunity.

Purpose of the Study:

• To investigate the therapeutic potential of SIRPα-silenced DCs against cervical cancer.
• To evaluate the effect of SIRPα knockdown on DC function and anti-tumor activity.

Main Methods:

• DCs were treated with a modified HPV16E7 protein.
• SIRPα was knocked down in DCs.
• Cytokine secretion (TNF-α, IL-12, IL-6) and IFN-γ secretion by T lymphocytes were measured.
• In vitro and in vivo anti-cancer activity was assessed against cervical cancer cells.

Main Results:

• SIRPα knockdown in DCs resulted in increased secretion of cytokines (TNF-α, IL-12, IL-6).
• Enhanced interferon-gamma (IFN-γ) secretion by T lymphocytes was observed.
• Significant in vitro and in vivo tumoricidal activity against cervical cancer cells was demonstrated.

Conclusions:

• SIRPα silencing in DCs enhances their anti-tumor immune response.
• SIRPα-silenced DC vaccination is a potential therapeutic strategy for cervical cancer.
• Targeting the SIRPα-CD47 axis offers a promising avenue for cancer immunotherapy.